Detalles de la búsqueda
1.
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
Health Qual Life Outcomes
; 6: 75, 2008 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-18831744
2.
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Dermatology
; 216(3): 260-70, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18187944
3.
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
J Dermatolog Treat
; 18(1): 25-31, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17365264
4.
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
J Dermatolog Treat
; 22(2): 65-74, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20443663
5.
Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.
Curr Med Res Opin
; 24(12): 3493-501, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19032131
Resultados
1 -
5
de 5
1
Próxima >
>>